Repositorio Dspace

Phase II Study of ENZAlutamide Combined With Hypofractionated Radiation Therapy (ENZART) for Localized Intermediate Risk Prostate Cancer

Mostrar el registro sencillo del ítem

dc.contributor.author Lara, Pedro-C
dc.contributor.author Rodríguez-Melcón, Juan-I
dc.contributor.author Palacios-Eito, Amalia
dc.contributor.author Lozano, Antonio
dc.contributor.author Hervás-Morón, Asunción
dc.contributor.author Villafranca, Elena
dc.contributor.author Gómez-Iturriaga, Alfonso
dc.contributor.author Sancho, Gemma
dc.contributor.author Maldonado, Xavier
dc.date.accessioned 2025-11-21T08:48:42Z
dc.date.available 2025-11-21T08:48:42Z
dc.date.issued 2022
dc.identifier.citation Lara PC, Rodríguez-Melcón JI, Palacios-Eito A, Lozano A, Hervás-Morón A, Villafranca E, et al. Phase II Study of ENZAlutamide Combined With Hypofractionated Radiation Therapy (ENZART) for Localized Intermediate Risk Prostate Cancer. Front Oncol. 14 de julio de 2022;12:891886.
dc.identifier.issn 2234-943X
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/22048
dc.description.abstract BACKGROUND: Intermediate-risk prostate cancer (PCa) is usually treated by a combination of external beam radiation therapy (EBRT) and a short course of androgen deprivation therapy (ADT). ADT is associated with multiple side effects, including weight gain, loss of libido, and hot flashes. In contrast, anti-androgen monotherapy is generally better tolerated in spite of higher rates of gynecomastia. OBJECTIVE: This study assessed the effectiveness of enzalutamide monotherapy combined with hypofractionated EBRT (Hypo-EBRT) for treating intermediate risk prostate cancer. METHOD: This trial was a multicenter, open-label phase II study of 6 months of enzalutamide monotherapy combined with Hypo-EBRT for intermediate-risk prostate cancer. Hypo-EBRT was initiated 8-12 weeks after initiating enzalutamide. The primary endpoint was PSA decline >80% measured at the 25th week of enzalutamide administration. Secondary end-points included assessment of toxicity, changes in anthropomorphic body measurements, sexual hormones, and metabolic changes. RESULTS: Sixty-two patients were included in the study from January 2018 to February 2020. A PSA decline of >80% was observed in all evaluable patients at the end of enzalutamide treatment and 92% achieved PSA values under 0.1 ngr/ml. All patients remain in PSA response (<80% reduction of the initial values) 6 months after the end of enzalutamide treatment. The most frequent adverse events were hypertension, asthenia, and gynecomastia. There were no significant changes in bone density, body mass index (BMI), or patient-reported outcomes (PROs). CONCLUSION: Enzalutamide monotherapy is very effective along with hEBRT in reducing PSA levels for patients with intermediate-risk prostate cancer. Longer follow-up is needed to confirm the potential use of this combination in future randomized trials.
dc.language.iso eng
dc.publisher Frontiers Media S.A.
dc.rights Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/es/  *
dc.title Phase II Study of ENZAlutamide Combined With Hypofractionated Radiation Therapy (ENZART) for Localized Intermediate Risk Prostate Cancer
dc.type info:eu-repo/semantics/article
dc.identifier.pmid 35912190
dc.relation.publisherversion https://www.frontiersin.org/articles/10.3389/fonc.2022.891886/full
dc.identifier.doi 10.3389/fonc.2022.891886
dc.journal.title Frontiers in Oncology


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta